Peptide Therapy

Peptides carry low immunogenicity because they mimic endogenous molecules, so the body does not mount a significant immune response against them. BPC-157 accelerates healing of tendons, ligaments, and muscles. BPC-157 protects the gut from NSAID-induced damage. The combination of BPC-157 and TB4 Active Fragment can penetrate and disrupt biofilms covering 80% of gut bacterial infections. TB4 Active Fragment retains the full spectrum of TB4's beneficial actions while eliminating mast cell activation risk. TB4 Active Fragment is 10 times more potent than full-length TB4 for antifibrotic activity. Approximately 80 peptides are FDA-approved in the United States, with roughly 100 approved globally and over 500 in clinical development. Peptide medicine is not taught in medical school or residency programs, requiring clinicians to self-educate on receptor physiology and mechanism of action. BPC-157 is a 15-amino-acid peptide isolated from human gastric juice in 1993. Peptides act by binding to cell surface receptors and triggering intracellular signaling cascades, notably PI3K and MAPK/ERK pathways. Peptides do not alter DNA; they are surface-level signaling molecules that are rapidly deg…